Author profile
Editorial team for Peptide Therapy Guide.
From this author
Anreicherung Modifizierter Peptide Ms Revisiting Anreicherung Modifizierter Peptide Ms:Practical Insights on Lyophilization Cycles Rational design based on molecular recognition principles enables construction…
Read guide →Today, a brief rundown of news from Novo Nordisk and Palvella Therapeutics, as well as updates from Gossamer Bio, Vanda Pharmaceuticals and Pfizer that you may have missed. Novo Nordisk on Tuesday announced pl…
Read guide →Peptide Boc Deprotection Key Structural Features That Define Peptide Boc Deprotection Bioactivity Growing consumer awareness of peptide biochemistry has reshaped how cosmetic formulations are evaluated by educ…
Read guide →Peptides And Ceramide Understanding Peptides And Ceramide:Formulator's Reference for Mixing Protocols Over decades of cumulative progress, the fundamental understanding of peptide folding, stability, and molec…
Read guide →Peptide Pen Cartridge Calculator Demystifying The Purity Standards Of Peptide Pen Cartridge Calculator:Sample Detection Guidelines Market data indicate a sustained upward trajectory for peptide-based materials…
Read guide →Today, a brief rundown of news involving Rocket Pharmaceuticals and Atara Biotherapeutics, as well as updates from Abivax, Gate Bioscience and Matchpoint Therapeutics that you may have missed. Rocket Pharmaceu…
Read guide →Dive Brief: Galapagos on Wednesday said it’s considering selling its cell therapy business , which previously had been the centerpiece of a restructuring plan. In January, the Belgian drugmaker said it would s…
Read guide →Star Therapeutics has raised $125 million in new venture funding that will help propel its experimental blood disease drug through late-stage testing. Initially formed as a “hub-and-spoke” biotech intending to…
Read guide →Dive Brief: Antibody drug specialist Genmab on Monday agreed to acquire Dutch biotechnology company Merus in an $8 billion deal centered around a drug that’s shown potential treating head and neck cancer. Per …
Read guide →Dive Brief: Cartography Biosciences, a San Francisco Bay Area biotechnology company, announced Thursday it raised a $67 million Series B round to propel its first drug prospect into clinical testing. Its lead …
Read guide →Today, a brief rundown of news involving Gilead Sciences and Stoke Therapeutics, as well as updates from the Centers for Disease Control and Prevention, AstraZeneca and Trogenix that you may have missed. Gilea…
Read guide →Procollagen Iii N Terminal Propeptide Understanding In Vitro Profiling Workflows for Procollagen Iii N Terminal Propeptide Customization of peptide sequences has become more accessible as automated synthesizer…
Read guide →Peptide Bonds Macromolecule Peptide Bonds Macromolecule Exploration:From Bioactive Design to Formulation Fit Understanding current industry trends requires examining how advanced peptide synthesis technologies…
Read guide →Having closed a nine-figure fundraising round, a newly launched biotechnology company hopes to rewire the immune system with drugs aimed at a special kind of nerve cell. Nilo Therapeutics debuted Wednesday , e…
Read guide →Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback . Today, a brief rundown of news involving AstraZeneca and Ascenta Capital, as well as updates from Expedition …
Read guide →Today, a brief rundown of news from Pfizer and Alkermes, as well as updates from Kura Oncology, Gilead Sciences and Zealand Pharma that you may have missed. Pfizer said Thursday it has closed its $10 billion d…
Read guide →Dive Brief: After months of back-and-forth announcements, Galapagos now plans to wind down its cell therapy business and focus resources on building a pipeline of new medicines through deals and acquisitions. …
Read guide →Pt21 Peptide Pt21 Peptide: Lessons Learned From My Peptide Purification Trials Modern biotech innovation supports individualized purification workflows for complex peptide samples. Cross-disciplinary innovatio…
Read guide →A vaccine Moderna has long been developing for the world’s most common congenital infection has failed a Phase 3 trial. The biotechnology company said late Wednesday that the shot, dubbed mRNA-1647, missed its…
Read guide →BioMarin Pharmaceutical is giving up on the hemophilia gene therapy Roctavian, announcing on Monday plans to offload a first-of-its-kind medicine once expected to become a future blockbuster. In a statement an…
Read guide →